HDAC9 and Patent ductus arteriosus: These trials have primarily defined the toxicity of HDAC inhibition in PDA patients and the findings have remained remarkably consistent across inhibitors of all HDAC classes and the various combinations of other chemotherapeutic agents paired with them.